HC Wainwright Reiterates Neutral Rating for LAVA Therapeutics (NASDAQ:LVTX)

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday, MarketBeat Ratings reports. They presently have a $1.50 target price on the stock, down from their prior target price of $2.00. HC Wainwright’s price objective suggests a potential upside of 16.28% from the stock’s previous close.

A number of other research firms also recently weighed in on LVTX. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Price Performance

LVTX opened at $1.29 on Thursday. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $6.47. The business has a 50-day moving average of $1.00 and a 200-day moving average of $1.43. The company has a market capitalization of $33.91 million, a PE ratio of -1.25 and a beta of 0.57.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings results on Tuesday, December 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). On average, equities research analysts expect that LAVA Therapeutics will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LVTX. Virtu Financial LLC acquired a new stake in LAVA Therapeutics in the 3rd quarter valued at approximately $32,000. BNP Paribas Financial Markets acquired a new stake in LAVA Therapeutics in the 4th quarter valued at approximately $40,000. Finally, Sanofi acquired a new stake in LAVA Therapeutics in the 4th quarter valued at approximately $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.